Abivax SA American Depositary Shares (ABVX)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Abivax as a speculative drug-development company, not a proven business. Its lead asset, obefazimod, is in Phase 3 for ulcerative colitis and Phase 2b for Crohn's disease, while the company has only 98 employees. At the 2026-10-26 close of $86.50, the market values it at $9.1B. On FairStock calculations from that close, the P/E is -14.27 and P/B is 16.57, so there are no earnings to support the price and the shares trade at a rich multiple to book value. FairStock return calculations show ROE of -252.35% and ROCE of -62.88%; trailing free cash flow is -$197.3M, a -2.2% FCF yield. The Piotroski F-Score is 1/9 and the FairStock Score is 16/100. The balance sheet shows D/E of 0.00, which helps, and Altman Z-Score is 55.11, but that model is not a substitute for clinical proof. Profit Growth is 7.45%, yet revenue growth is not meaningful in the data, and the computed Lynch category is none because only zero years of filed results are available and three are needed. As Graham would say, I need a margin of safety in facts; here the key facts are future trial outcomes. Buffett would ask for a durable moat, but no approved product or commercial record is given. The stock's 52-week range is $69.81-$148.83, beta is -0.25, and there is no dividend. This is a binary pipeline story: potential is real, but the current valuation depends on events, not demonstrated profits.

In plain English: The company is a drug developer still testing its main medicine for chronic gut inflammation. It is not yet profitable, spends more cash than it brings in, and its share price looks high compared with its reported net worth. By the numbers shown, the business looks weak and the stock looks expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer